GAITHERSBURG, Md., Aug. 03, 2015 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its second quarter 2015 financial and operating results after the close of U.S. financial markets on Monday, August 10, 2015.
In addition, management will host a conference call to discuss the quarterly results and provide an update on corporate activities.
Conference call details are as follows:
| Date: | August 10, 2015 |
| Time: | 4:45 pm US Eastern Time (ET) |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287–9331 (International) |
| Via web: | www.novavax.com, “Investors”/ “Events” |
Conference call replay:
| Dates: | Starting at 7:30 pm ET on August 10, 2015 until midnight August 17, 2015 |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) |
| Passcode: | 97557844 |
| Via web: | www.novavax.com, “Investors”/ “Events” |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company’s website, www.novavax.com.